Mount Sinai Researchers Determine Significant Beta Cell Proliferation Using Combination of Pharmacologic and Genetic Inhibition
A major breakthrough in diabetes treatment has been achieved by researchers at Mount Sinai, who have combined pharmacologic and genetic inhibition to stimulate the proliferation of beta cells. Beta cells are responsible for producing insulin in the pancreas, and the innovative approach employed by the researchers holds great promise for restoring the body's insulin production capacity.
The breakthrough involves the use of two different classes of drugs that have demonstrated the highest rate of proliferation in adult human beta cells. One drug inhibits dual specificity tyrosine-regulated kinase 1A (DYRK1A), while the other targets members of the transforming growth factor beta superfamily (TGFβSF). When these drugs are administered together, they trigger beta cell proliferation at an impressive rate of 5 to 8 percent per day.
This drug combination shows tremendous potential for facilitating beta cell regeneration at a rate that is suitable for effective diabetes treatment. This is particularly important for type 1 diabetes, where the autoimmune response leads to the destruction of insulin-producing beta cells. Additionally, a deficiency of functional beta cells is also a key factor in type 2 diabetes, the most common form of the disease in adults.
The development of drugs that can increase the number of healthy beta cells is a top priority in diabetes research. One such drug, harmine, has shown promise in inducing sustained division and multiplication of adult human beta cells in laboratory settings. Treatment with harmine has even restored normal blood sugar control in mice that had their beta cells replaced with human beta cells.
Although the proliferation rate achieved thus far falls short of the rapid expansion needed for effective beta cell augmentation in individuals with diabetes, the combination of drugs represents a significant advancement in diabetes research. It is one of the most remarkable series of discoveries in the field, bringing us closer to developing drugs that can combat this disease more effectively.
